Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 18 Oct 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 18 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 02 Nov 2018 Status changed from recruiting to active, no longer recruiting.